Savonix and Fujitsu Connected Technologies Limited Partner to Introduce Savonix Mobile App on Raku-Raku Smartphone F-42A
Savonix, a global leader in digital cognitive health testing, and Fujitsu Connected Technologies Limited (FCNT), one of the major smartphone manufacturers in Japan, unveiled Savonix Mobile–a digital cognitive testing app–on the Raku-Raku Smartphone F-42A.
More than 4.6 million people in Japan are suffering from some form of dementia, with the total expected to soar to about 7.3 million people – or one in five Japanese aged 65 or over – by 2025. Japan’s government last year announced aims to reduce dementia cases by 6 percent in those aged 70 and older over the next six years.
Savonix Mobile, pre-installed on the Raku-Raku Smartphone F-42A, will allow users to test their cognition across eight brain functions such as executive function, working memory, and impulse control. Users will immediately receive test results within the app and will be able to take action to manage their cognitive health. Savonix Mobile detects mild cognitive impairment 93 percent of the time. For this reason, testing cognition is a good way to monitor your brain health over time. Recent studies presented at this year’s Alzheimer’s Association International Conference in July showed that up to 40 percent of dementias may be prevented by changing health habits such as diet, smoking, alcohol use, and sleep. Understanding your lifestyle risks can help you make smarter choices about brain health.
The Raku-Raku Smartphone will also house a pedometer and other important healthcare pre-installed applications to support and manage the user’s health.
“We’re excited about our partnership with FCNT as it will put easy and accurate cognitive testing into the hands of people who need it. This is impactful and aligns with how Japan and Japanese companies like FCNT are leading globally on the prevention of dementia,” said Savonix Founder and CEO Dr. Mylea Charvat. “Our digital cognitive assessment platform enables people to assess and monitor their brain health regularly and to incorporate lifestyle advice to improve brain wellness.”
“It is our great pleasure to have our Raku-Raku Smartphone F-42A equipped with the Savonix Mobile App,” said Katsumi Takada, President & Representative Director at FCNT. “This adoption enables services that support maintaining brain health and reducing the risk of dementia for users. We expect that this will make people more conscious about their health and help them lead a healthier life.”
About Savonix
A global leader in cognitive health, Savonix delivers the only neuropsychology platform in the market. Savonix provides digital cognitive health solutions and empowers healthcare providers, payers, and researchers to evaluate and leverage results to improve health and treatment outcomes. Developed by clinical neuropsychologists and digital health technology experts, the Savonix Cognitive Assessment is an accurate, accessible, and affordable tool available for download on all mobile devices. To learn more about Savonix, visit Savonix.com.
About Fujitsu Connected Technologies
Fujitsu Connected Technologies Limited was established in February 2016 through the spinoff of Fujitsu Limited’s mobile phone business. To create a future where people live their lives fully with peace of mind, FCNT connects people, things, and services in a more comfortable way with transcendental ideas and advanced technologies. FCNT has led the way in its integration of healthcare technologies into mobile phones since they introduced the world's first mobile phone with a pedometer in 2003. For more details, please visit https://www.fujitsu.com/jp/group/fcnt/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005016/en/
Contact information
Savonix
Reynald Hiole
+1 415.919.7421
rhiole@savonix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 03:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 01:34:00 EET | Press release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 22:37:00 EET | Press release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 18:00:00 EET | Press release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 17:57:00 EET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom